Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity

[1]  T. Enomoto,et al.  Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. , 2012, Gynecologic oncology.

[2]  N. Yaegashi,et al.  Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). , 2012, Oncology reports.

[3]  Mitsuaki Suzuki,et al.  Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies , 2012, Cancer Chemotherapy and Pharmacology.

[4]  N. Zaffaroni,et al.  Targeting DNA topoisomerase I with non-camptothecin poisons. , 2012, Current medicinal chemistry.

[5]  R. Bast,et al.  The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. , 2011, Journal of the National Cancer Institute.

[6]  J. Diffley,et al.  Positive Supercoiling of Mitotic DNA Drives Decatenation by Topoisomerase II in Eukaryotes , 2011, Science.

[7]  S. Parsons,et al.  In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? , 2010, Gynecologic oncology.

[8]  N. Yaegashi,et al.  Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study) , 2010, International Journal of Gynecologic Cancer.

[9]  Tadao Tanaka,et al.  Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition , 2010, International Journal of Clinical Oncology.

[10]  Guoqiang Chen,et al.  Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis , 2009, Apoptosis.

[11]  M. Henriksson,et al.  Camptothecin‐induced apoptosis is enhanced by Myc and involves PKCdelta signaling , 2007, International journal of cancer.

[12]  A. Berrington de González,et al.  Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis , 2004, British Journal of Cancer.

[13]  Tsuyoshi Saito,et al.  Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. , 2004, Gynecologic oncology.

[14]  J. Bergerat,et al.  Signal transduction pathways of taxanes-induced apoptosis. , 2003, Current medicinal chemistry. Anti-cancer agents.

[15]  Y. Segev,et al.  Replication and/or separation of some human telomeres is delayed beyond S-phase in pre-senescent cells , 2002, Chromosoma.

[16]  E. Sausville,et al.  Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels , 2000, Cell Death and Differentiation.

[17]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[18]  R. Kudo,et al.  Cloning and characterization of a cDNA fragment coding beta-casein-like protein preferentially expressed in cervical adenocarcinoma cell line CAC-1. , 1998, Cancer letters.

[19]  M. Davey,et al.  Paclitaxel sensitizes multidrug resistant cells to radiation , 1996, Anti-cancer drugs.

[20]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[21]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[22]  M. Horwitz,et al.  Effects of camptothecin on the breakage and repair of DNA during the cell cycle. , 1973, Cancer research.